Piramal Pharma Limited (PPL) announced its standalone and consolidated financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2025. The company reported a consolidated revenue from operations of ₹2,140 crore for Q3 FY26, a decrease of 3% year-on-year from ₹2,204 crore in Q3 FY25. For the nine-month period, revenue stood at ₹6,117 crore, down 4% from ₹6,397 crore in the prior year. The Contract Development and Manufacturing Organization (CDMO) segment saw a revenue decline of 9% in Q3 FY26 to ₹1,166 crore. The Complex Hospital Generics (CHG) business reported a 2% increase in revenue to ₹668 crore, while the Consumer Healthcare (PCH) business grew by 20% to ₹334 crore. Consolidated EBITDA for the quarter was ₹239 crore, a 32% decrease compared to ₹350 crore in Q3 FY25. Profit After Tax (PAT) after exceptional items was a loss of ₹136 crore, compared to a profit of ₹4 crore in the same period last year. This was impacted by inventory destocking in a key product, slower early-stage order inflows due to biopharma funding uncertainties, and regulatory delays in the inhalation anesthesia segment. Despite the challenges, Piramal Pharma is observing early signs of recovery, with a significant pick-up in Request for Proposals (RFPs) and order inflows since October 2025, driven by improved biopharma funding and increased M&A activities in the US. The company is also advancing its strategic initiatives, including the acquisition of Kenalog® for up to US$100 million and a US$90 million investment to expand its Lexington and Riverview facilities. Piramal Pharma Limited will host an earnings conference call on January 29, 2026, from 9:30 AM to 10:15 AM IST to discuss these results.
